Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Docetaxel plus zoledronic acid vs zoledronic acid in prostate cancer with bone metastases
2008-002838-30Phase 2Terminated
- Sponsor
- Istituto Romagnolo per lo Studio dei Tumori "Dino Amadori"
- Start
- Mar 2009
- Modality
- Classical Binding Small Molecules → Small Molecules, Covalent Small Molecules → Small Molecules, Nucleic Acid-Directed Small Molecules → Small Molecules
- Countries
- 1
01
Overview
Phase 2, randomised trial in prostate cancer (PCa) and bone metastases comparing Docetaxel + zoledronic acid with Zoledronic acid alone (2 arms). Primary endpoint: Progression-free survival. Started Mar 2009; status: terminated.
02
Drugs
docetaxelzoledronic acid
03
Conditions
prostate cancer (PCa)bone metastases
Beyond the preview
Go deeper on 2008-002838-30.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2008-002838-30.